Industry
Pharmaceutical Products companies
VCMC tracks 31,359 companies in Pharmaceutical Products. 1,028 of them have raised a venture or growth round, $65.08B in total, with a median round of $20M; 437 raised since 2024. 1,000 of the 1,028 have a VCMC valuation; the median is $91.4M.
31,359
companies tracked
1,028
venture-backed
3% of those tracked
$65.08B
raised in total
by 985 companies
$20M
median round
of 1,407 rounds with an amount
$91.4M
median valuation
of 1,000 companies valued
Values cover private companies only; public companies are not included.
By their latest round, most are at Series A (322 of 1,028).
- Pre-seed 36
- Seed 200
- Series A 322
- Series B 197
- Series C and later 260
- Stage not stated 13
The companies
Pharmaceutical Products companies
The 50 venture-backed companies below are this page's list; Resilience has raised the most ($2.02B).
| # | Last round | History | Range | Trend | Grade | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Resilience Blue Ash, United States | Series D Jun 2022 $625M | $3.3B | $633M – $13.0B | $2.8B (-13%) | $1.1B | 59% | 1,307 | flat | D | |
| 2 | ElevateBio Waltham, United States | Series D May 2023 $401M | $2.4B | $693M – $9.9B | $1.7B (-30%) | $720M | 79% | 450 | down | D | |
| 3 | Cerevel Cambridge, United States | Debt Aug 2022 $300M | $755M | $100M – $2.4B | $679M (-10%) | $151M | 46% | 140 | unknown | D | |
| 4 | Azurity Pharmaceuticals Woburn, United States | Growth Equity Mar 2026 $1.10B | $13.3B | $8.4B – $21.3B | $14.0B (+6%) | $1.3B | 0% | 1,062 | growing | B | |
| 5 | Kailera Therapeutics Waltham, United States | Series B Oct 2025 $600M | $5.5B | $2.6B – $7.8B | $5.5B (0%) | $608M | 0% | 26 | unknown | B | |
| 6 | Essential Pharma Egham, United Kingdom | Growth Equity Dec 2024 $946M | $11.7B | $5.3B – $17.8B | $11.7B (0%) | $1.1B | 0% | 122 | up | C | |
| 7 | Verdiva Bio Guildford, United Kingdom | Growth Equity Sep 2025 $457M | $5.0B | $3.1B – $7.0B | $5.0B (0%) | $486M | 0% | 78 | growing | B | |
| 8 | Genetic Fisciano, Italy | Growth Equity May 2025 $770M | $8.6B | $4.0B – $13.1B | $8.6B (0%) | $847M | 0% | 229 | flat | B | |
| 9 | RemeGen Yantai, China | Other Jan 2026 $650M | $1.1B | $63.5M – $1.6B | $1.1B (0%) | $110M | 0% | 3 | unknown | D | |
| 10 | Amoun Pharmaceutical Cairo, Egypt | Growth Equity Mar 2021 $740M | $4.3B | $298M – $10.2B | $4.2B (-1%) | $814M | 4% | 1,127 | flat | D | |
| 11 | Cellares South San Francisco, United States | Series D Jan 2026 $257M | $4.0B | $2.3B – $6.1B | $4.3B (+8%) | $470M | 0% | 327 | up | B | |
| 12 | ITM Radiopharma Garching bei München, Germany | Debt May 2025 $263M | $2.6B | $747M – $4.0B | $1.9B (-26%) | $256M | 0% | 661 | up | C | |
| 13 | Nimbus Therapeutics Boston, United States | Growth Equity Sep 2023 $210M | $1.2B | $283M – $2.9B | $1.0B (-14%) | $197M | 28% | 102 | flat | D | |
| 14 | Formation Bio New York, United States | Series D Jun 2024 $372M | $6.0B | $1.5B – $8.5B | $4.0B (-34%) | $660M | 0% | 198 | flat | C | |
| 15 | AdvanCell Sydney, Australia | Series D Jul 2026 $315M | $3.1B | $2.1B – $5.4B | $3.8B (+23%) | $480M | 0% | 101 | growing | B | |
| 16 | Sanfer México, Mexico | Growth Equity Aug 2019 $500M | $4.5B | $346M – $6.9B | $4.5B (0%) | $550M | 0% | 2,156 | up | D | |
| 17 | Tubulis Planegg, Germany | Series C Oct 2025 $358M | $2.7B | $1.8B – $3.1B | $2.7B (0%) | $326M | 0% | 77 | up | A | |
| 18 | Rakuten Medical San Diego, United States | Series F Jan 2026 $100M | $1.6B | $973M – $2.4B | $1.6B (0%) | $197M | 21% | 132 | flat | B | |
| 19 | Sail Biomedicines Cambridge, United States | Growth Equity Jul 2026 $465M | $5.2B | $3.4B – $8.1B | $5.0B (-3%) | $512M | 67% | 108 | flat | B | |
| 20 | Abcuro Newton, United States | Series D Aug 2026 $66M | $826M | $542M – $1.3B | $770M (-7%) | $118M | 97% | 36 | shrinking | B | |
| 21 | Synthego Redwood City, United States | Series E Feb 2022 $200M | $1.5B | $115M – $3.3B | $1.5B (-1%) | $252M | 16% | 163 | unknown | D | |
| 22 | Orca Bio Menlo Park, United States | Debt Jan 2026 | $4.1B | $2.2B – $6.6B | $4.3B (+6%) | $475M | 0% | 377 | growing | B | |
| 23 | Ollin Biosciences Austin, United States | Series B Jun 2026 $330M | $2.0B | $1.2B – $3.6B | $2.6B (+31%) | $283M | 0% | 28 | unknown | B | |
| 24 | Israel | Series A Dec 2025 $165M | $1.3B | $513M – $2.1B | $1.4B (+10%) | $240M | 0% | 38 | up | C | |
| 25 | Ougrée, Belgium | Other Dec 2021 $51M | $57.1M | $9.80M – $227M | $55.0M (-4%) | $43.4M | 59% | 50 | flat | D | |
| 26 | Mont-Saint-Guibert, Belgium | Other Sep 2026 $12M | $134M | $7.71M – $288M | $126M (-6%) | $27.2M | 6% | 58 | flat | D | |
| 27 | Singapore | Series B Jun 2023 $40M | $174M | $28.6M – $472M | $140M (-20%) | $41.5M | 30% | 18 | flat | D | |
| 28 | Marche-en-Famenne, Belgium | Series A Nov 2024 $57M | $555M | $241M – $926M | $510M (-8%) | $98.6M | 19% | 39 | growing | C | |
| 29 | Wilmington, United States | Series A Oct 2026 $47M | $269M | $172M – $715M | $470M (+75%) | $65.8M | 0% | 34 | growing | C | |
| 30 | Daejeon, South Korea | Series C Feb 2022 $45M | $94.6M | $21.5M – $734M | $88.3M (-7%) | $63.2M | 79% | 17 | down | D | |
| 31 | Clonmel, Ireland | Series B Oct 2023 $35M | $72.9M | $40.9M – $175M | $40.4M (-45%) | $35.9M | 97% | 33 | shrinking | C | |
| 32 | Norway | Debt Apr 2026 $1.5M | $50.2M | $23.7M – $165M | $43.7M (-13%) | $39.0M | 97% | 31 | shrinking | C | |
| 33 | Daejeon, South Korea | Series C Jul 2026 $8.6M | $73.6M | $44.8M – $135M | $88.6M (+20%) | $11.2M | 0% | 10 | unknown | B | |
| 34 | Phagos Suresnes, France | Series A Oct 2025 $29M | $295M | $108M – $449M | $295M (0%) | $45.0M | 0% | 78 | growing | C | |
| 35 | Elverum, Norway | Growth Equity Apr 2024 $21M | $235M | $64.8M – $409M | $203M (-14%) | $26.5M | 20% | 89 | flat | C | |
| 36 | Charleroi, Belgium | Series C Dec 2020 $24M | $27.1M | $9.39M – $105M | $25.5M (-6%) | $22.3M | 97% | 24 | shrinking | D | |
| 37 | Kyoto, Japan | Other Jul 2026 $11M | $163M | $56.3M – $248M | $122M (-25%) | $20.6M | 0% | 16 | up | C | |
| 38 | Diepenbeek, Belgium | Series B Oct 2021 $18M | $58.8M | $4.45M – $136M | $54.2M (-8%) | $14.8M | 15% | 15 | flat | D | |
| 39 | Galway, Ireland | Series A Jan 2022 $22M | $26.1M | $6.44M – $195M | $25.8M (-1%) | $26.3M | 89% | 14 | down | D | |
| 40 | Daejeon, South Korea | Series B Sep 2020 $21M | $46.9M | $6.63M – $178M | $44.9M (-4%) | $24.3M | 47% | 17 | flat | D | |
| 41 | South Korea | Series B Feb 2022 $17M | $8.91M | $3.36M – $64.0M | $8.27M (-7%) | $9.80M | 97% | 9 | down | D | |
| 42 | Kyoto, Japan | Series C May 2026 $5.3M | $46.9M | $27.5M – $82.9M | $54.5M (+16%) | $6.89M | 0% | 13 | unknown | B | |
| 43 | Nigeria | Series A Aug 2023 $8.0M | $58.2M | $5.97M – $102M | $58.2M (0%) | $12.2M | 0% | 210 | unknown | D | |
| 44 | Liège, Belgium | Series A Apr 2024 $17M | $49.2M | $20.9M – $181M | $29.1M (-41%) | $21.5M | 96% | 17 | down | D | |
| 45 | Busan, South Korea | Series B Mar 2021 $16M | $27.9M | $4.65M – $146M | $26.1M (-6%) | $18.9M | 58% | 16 | flat | D | |
| 46 | Derio, Spain | Series A Jan 2023 $16M | $19.4M | $9.82M – $54.0M | $14.5M (-25%) | $22.4M | 97% | 25 | shrinking | C | |
| 47 | Mont-Saint-Guibert, Belgium | Series A Apr 2018 $16M | $108M | $3.93M – $219M | $108M (0%) | $22.0M | 0% | 17 | unknown | D | |
| 48 | Cantanhede, Portugal | Series C Dec 2024 $16M | $178M | $93.0M – $297M | $162M (-9%) | $24.4M | 28% | 60 | growing | B | |
| 49 | Casablanca, Morocco | Growth Equity Apr 2025 $15M | $154M | $68.3M – $234M | $154M (0%) | $16.9M | 0% | – | flat | C | |
| 50 | Valink Therapeutics London, United Kingdom | Seed Nov 2023 $7.8M | $115M | $13.8M – $175M | $114M (0%) | $22.5M | 0% | 30 | up | D |
Showing 50 of 31,359. Load more lists every other company here, 50 at a time.
Valuations
How these companies are valued
1,000 of the 1,028 venture-backed companies here have a VCMC valuation; the median is $91.4M. A company acquired after its last round keeps its last value as a private company and is left out of the median. 29 companies have disclosed a valuation; for the rest VCMC's valuation is the only number. Each valuation comes with a range, from a low to a high scenario, and a prediction for a year from now. Values cover private companies only; public companies are not included. How VCMC values companies.
Investors
Who backs them
Firms that backed two or more of these companies. RA Capital backed 35, Novo Holdings 28.
- 35 companies, led 8
- 28 companies, led 6
- 27 companies, led 5
- 24 companies, led 6
- 23 companies, led 9
- Alexandria Venture Investments 20 companies, led 1
- EQT 15 companies, led 6
- Bpifrance 15 companies, led 3
- 14 companies, led 6
- 14 companies, led 3
- ARCH Venture Partners 13 companies, led 4
- Eli Lilly and Company 13 companies
Recent rounds
Latest funding
176 rounds from Oct 2025 to Sep 2026, $10.15B with a disclosed amount.
- Series B, with Novo Holdings and Ljungström family office $72M 30 Sep 2026
- Series B, led by DeepWork Capital $9.5M 30 Sep 2026
- Series A, with Mission BioCapital and Novo Holdings $78M 29 Sep 2026
- Pre-seed, with Elmstead Partners and Chisos Capital $2.4M 25 Sep 2026
- Growth, with Lotus One Investment Pte. Ltd. and Valquest Partners $7.6M 23 Sep 2026
- Series A, with SPRIND and Huma $14M 23 Sep 2026
- Series A, with Brightlands Venture Partners and LIOF $16M 17 Sep 2026
- Series C, led by Forbion $123M 16 Sep 2026
- Seed $1.8M 10 Sep 2026
- Seed, with Kotak Alternate Asset Managers and Alkemi $7.2M 8 Sep 2026
- Series A, led by Biovance Capital $13M 7 Sep 2026
- Seed, led by RRE Ventures $7.1M 4 Sep 2026
Browse
Related groups
Pharmaceutical Products by city
Pharmaceutical Products by country
Other industries
Questions
Frequently asked
How many pharmaceutical Products companies does VCMC track?
31,359. 1,028 of them have raised a venture or growth round.
How much have pharmaceutical Products companies raised?
$65.08B in total across the 985 with a known amount; the median round is $20M. 437 raised a round since 2024.
Which pharmaceutical Products companies have raised the most?
Resilience ($2.02B), ElevateBio ($1.25B), Cerevel ($1.22B).
Which investors back pharmaceutical Products companies most often?
RA Capital (35 companies), Novo Holdings (28 companies), OrbiMed (27 companies).
What are pharmaceutical Products companies worth?
The median VCMC valuation is $91.4M across 1,000 companies; companies acquired after their last round are left out. Values cover private companies only; public companies are not included.
What was the latest funding round?
AnaCardio raised a Series B round of $72M (Sep 2026), with Novo Holdings and Ljungström family office.